A Study of RoActemra/Actemra (Tocilizumab) in Combination With DMARDs Versus Current Best Practice DMARD Therapy in Patients With Rheumatoid Arthritis

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT01251120
First received: November 30, 2010
Last updated: March 3, 2014
Last verified: March 2014
  Purpose

This randomized, open-label, parallel-group study will assess the effect on disease remission of RoActemra/Actemra (tocilizumab) in combination with disease-modifying antirheumatic drugs (DMARDs) versus current best practice non-biologic DMARD therapy in patients with moderate-to-severe active rheumatoid arthritis. Patients who are randomly assigned to the RoActemra/Actemra treatment group will receive 8 mg/kg RoActemra/Actemra intravenously every 4 weeks. The anticipated time on study treatment is 12 months.


Condition Intervention Phase
Rheumatoid Arthritis
Drug: tocilizumab [RoActemra/Actemra]
Drug: DMARD
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Pragmatic, Randomized, Parallel Group Study of the Effect on Disease Remission, Work Productivity and Tolerability of Tocilizumab in Combination With DMARDs and Individually Designed Best Practice DMARD Therapy in Patients With Early, Moderate to Severe Rheumatoid Arthritis

Resource links provided by NLM:


Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Proportion of patients achieving disease remission (DAS28 <2.6) [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Work Productivity (absence from work) [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Proportion of patients achieving disease remission (DAS28<2.6) [ Time Frame: 6 months ] [ Designated as safety issue: No ]
  • Proportion of patients achieving responses according to American College of Rheumatology (ACR) criteria [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Proportion of patients achieving clinical disease activity index (CDAI) remission [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Safety (incidence of adverse events) [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Quality of life questionnaire [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Enrollment: 2
Study Start Date: November 2011
Study Completion Date: January 2013
Primary Completion Date: January 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: tocilizumab [RoActemra/Actemra]
8 mg/kg intravenously every 4 weeks plus background DMARDs (including methotrexate)
Active Comparator: 2 Drug: DMARD
Non-biologic DMARDs (including methotrexate) according to current best practice

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adult patients, over the age of 18 years
  • Diagnosis of moderate-to-severe active early rheumatoid arthritis (RA) of less than 2 years duration
  • DAS28 >3.2
  • Swollen joint count (SJC) >/=6 (66 joint count), and tender joint count (TJC) >/=6 (68 joint count)
  • Patients who have received DMARDs (including methotrexate) for 3-7 months

Exclusion Criteria:

  • Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months after baseline
  • Rheumatic autoimmune disease other than rheumatoid arthritis (secondary Sjögrens syndrome or nodulosis with RA is permitted)
  • Functional class III or IV as defined by ACR Classification of Functional Status in Rheumatoid Arthritis
  • Prior history of or current inflammatory joint disease other than RA
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01251120

Locations
Finland
Helsinki, Finland, 00029
Hämeenlinna, Finland, 13530
Jyväskylä, Finland, 40620
Kuopio, Finland, 70101
Riihimäki, Finland, 11101
Rovaniemi, Finland, 96101
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

No publications provided

Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT01251120     History of Changes
Other Study ID Numbers: ML25346
Study First Received: November 30, 2010
Last Updated: March 3, 2014
Health Authority: Finland: Finnish Medicines Agency

Additional relevant MeSH terms:
Arthritis
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases

ClinicalTrials.gov processed this record on September 18, 2014